대한뉴팜

Daehan New Pharm participated as an exhibitor at the International Beauty Expo (CIBE) held in Guangzhou, China, from September 4th to 6th, 2016, to promote its Luthione cosmetics line. The International Beauty Expo is Asia's largest cosmetics and beauty professional exhibition, featuring over 3,800 companies from 26 countries. At the event, Daehan New Pharm showcased seven Luthione cosmetics products, including skin toner, lotion, cream, eye cream, and mask packs, along with medical devices, receiving significantly higher interest than expected. Luthione cosmetics differentiate themselves from typical products by using cucumber extracts instead of purified water commonly found in cosmetics. Adhering to a “10-Free” policy, the products minimize chemical ingredients by excluding parabens, artificial colors, surfactants, benzyl alcohol, artificial fragrances, and more. Instead, the formula includes eight types of vitamins to maximize skin nutrition. Moreover, the inclusion of glutathione and a luminous network formula enhances whitening and radiant skin effects. The Luthione brand was already well recognized among Chinese tourists (Youkers) visiting for beauty treatments, known for its skin whitening injection. Leveraging this brand recognition, Daehan New Pharm expanded into the cosmetics field with Luthione and plans to actively market the brand to ensure successful establishment in the Chinese market.

An export contract was signed with Vellesshima Medical, located in Tokyo, for PPC formulation medicine (product name: Ripolysis) at a scale of 3,000 vials per month. Daehan New Pharm has been regularly exporting 10,000 vials per month of 50ml Vitamin C to Japan since 2011. Although entering the Japanese market is initially challenging, once established, it allows for long-term and stable supply without price constraints. Daehan New Pharm plans to successfully launch Lipolysis, develop additional products, and actively expand into the Japanese market. Since receiving the $10 million Export Tower award in 2015, the company has been more actively promoting overseas exports. It is strengthening partnerships in strategic overseas bases such as Russia and vigorously expanding into new markets. Well-being products inspired by the Korean Wave have shown good responses in China and Southeast Asia, leading to active overseas market development.

Daehan New Pharm launched New-DN Injection, containing Polydeoxyribonucleotide (known as "salmon injection ingredient"), in April. The product was developed primarily by Korea BMI and is jointly marketed by Daehan New Pharm and two other companies. Within one week of launch, the initial batch of orders was fully distributed to the market, including wholesalers and clinics, with the second batch already awaiting supply, indicating a successful release and expected significant contribution to sales. The overall market for salmon injection ingredients is currently estimated to be around 40 billion KRW but is predicted to exceed 50 billion KRW in 2016 due to the increasing number of companies selling these products. New-DN Injection, well known for its salmon injection ingredient, has primarily been used as an adjunct therapy for pain relief in anesthesiology and orthopedics. Due to its tissue regeneration effects, it is also used in the skin and beauty sectors in combination with HA fillers, known as “water glow injections.” Daehan New Pharm is already well recognized in the skin beauty area with products like Luthione Injection and Cindella Injection. Unlike other co-marketing partners, Daehan New Pharm holds confidence that it can lead and expand the therapeutic market for salmon injection ingredients. Current sales data show that about 50% of New-DN Injection’s client base comes from dermatology. The company plans to achieve sales of over 3 billion KRW for New-DN Injection in 2016 and aims to reach 10 billion KRW in 2017. Leveraging its experience from New-DN Injection, Luthione Injection, and Cindella Injection, Daehan New Pharm plans to expand further into the skin beauty business, including fillers and beauty devices.

Daehan New Pharm, listed on KOSDAQ (054670), posted first-quarter 2016 results with sales growing 15.1% year-over-year to 24.086 billion KRW and operating profit increasing 15.2% to 2.604 billion KRW, maintaining a high-growth trend for the fourth consecutive year. The company’s strategy focuses on expanding its product portfolio, strengthening customer relationships through creative solution-based sales, overcoming limits with proactive management, and continuously creating value innovation centered on talent management while concentrating on core activities.

Daehan New Pharm’s export pharmaceutical product, Trimedat, which received the $10 million Export Tower award in 2015, was honored at the Russian Pharma Awards. This award ceremony is one of the most important events in the Russian pharmaceutical industry, with over 4,000 doctors voting directly to determine the winning medicines. The award signifies that Trimedat tablets are recognized as a reliable and excellent product in the Russian market. This achievement was made possible through close collaboration with Russian partners over more than ten years. In 2015, Trimedat recorded sales of $2.3 million, with a target of $3.5 million for the current year. To increase exports to Russia, Daehan New Pharm is in the process of registering one injectable product, one antibiotic, and one oral medication. Upon completion of these three registrations, the company expects to achieve export sales of $10 million solely from the Russian market. To sustain export growth, Daehan New Pharm is strategically focusing on Russia, China, and Southeast Asia as export bases, while also developing new markets in untapped regions such as Cuba, and expanding in growing markets like Pakistan, Azerbaijan, and Mongolia. Additionally, the company is concentrating its efforts on exporting veterinary pharmaceuticals to Middle Eastern markets. Currently, Daehan New Pharm has established a worldwide network through strategic partnerships in over 20 countries and more than 60 alliances globally.

- Sustained substantial qualitative growth (25.4% sales growth, 77.6% ordinary profit growth)- Entered the 10 billion KRW operating profit club (operating profit of 10.052 billion KRW)- Announced new management philosophy and vision Daehan New Pharm had a remarkable 2015. Total sales for 2015 reached 90.23 billion KRW, a 25.4% increase year-on-year. Operating profit rose 27.1% to 10.052 billion KRW, and ordinary profit surged 77.6% to 6.422 billion KRW, maintaining a high-growth trend fueled by continuous 20% growth and improved financial structure. Entering the 10 billion KRW operating profit club holds significant meaning. This growth reflects strategic innovation and relentless drive for evolution and development: Successful entry into the elderly chronic disease market through continuous new product launches and strategic focus, pursuing qualitative growth in generics. Strengthening of its well-being portfolio by diversifying functional health foods, cosmetics, and obesity products, enhancing its domestic leading position. Building a stable growth foundation through restructuring the animal medicine business and focusing on core product groups, bolstering growth potential with specialized bio-technology products aimed at the swine market. Opening of a bio R&D center in Osong Advanced Medical Complex conducting immune cell and stem cell research and enhancing efficiency through active industry-academia cooperation. Strengthening partnerships at overseas strategic bases such as Russia and expanding overseas business while well-being products influenced by Hallyu (Korean wave) have received positive feedback in China and Southeast Asia. As a result, Daehan New Pharm received the "$10 Million Export Tower" award at the 52nd Trade Day in December. At the end of the year, marking its 30th anniversary, Daehan New Pharm reestablished its management philosophy under "Daehan New Pharm sharing health, happiness, and warmth," based on human-centered, creative, and ethical management. It announced a new vision, "New Platform for Life Care," focusing on bio-business as a core, shared by all employees. In 2016, under the slogan "Smart Start for The Great DHNP," Daehan New Pharm will strengthen its sales responsibility system, activate HR and sales execution programs, and accelerate strategic innovation focusing on bio and overseas business as new growth engines to ensure a successful second leap.

On December 15, 2015, Daehan New Pharm signed an agreement with Professor Hwa-Young Yoon of the College of Veterinary Medicine at Seoul National University to conduct joint research and provide technical consultation for the industrialization of stem cells for companion animals. Going forward, both parties plan to develop stem cells that can be widely applied to intractable diseases such as spinal cord injuries, degenerative arthritis, autoimmune disorders, and chronic renal failure through innovations in stem cell culture technology and various clinical trials. The developed technology will first be applied in animal hospitals and later expanded to the development of stem cell therapies for human use. In addition, Daehan New Pharm plans to enhance its stem cell technologies currently under development and ownership to accelerate market entry, while also discussing potential export opportunities with overseas buyers in rapidly growing companion animal markets such as China and Vietnam, where economic growth and rising income levels are fueling expansion.

Daehan New Pharm, the recipient of the 10 Million Dollar Export Tower Award at the 52nd Trade Day, has launched a new cosmetics line utilizing its wellness prescription expertise. Through this initiative, the company is expanding its wellness business into immune enhancement, medical devices, and beauty, thereby strengthening its growth engines. The newly introduced “Luthione Skincare” line primarily targets the Chinese market. Daehan New Pharm has signed a supply and sales agreement with Shenzhen Neo Med Hospital Management, and with a long-term strategic perspective, plans to systematically develop and manage the market. As part of this plan, the company will export an initial shipment of 200,000 units to launch the product in China. By leveraging its successful domestic wellness marketing experience, Daehan New Pharm expects that the introduction of Luthione Skincare in China will create synergy with its existing wellness products and enhance its brand image as a leading wellness specialist.

- Daehan New Pharm Wins the “10 Million Dollar Export Tower” at the 52nd Trade Day- CEO Bae Gun-Woo Receives Commendation from the Minister of Trade, Industry and EnergyDaehan New Pharm received the “10 Million Dollar Export Tower Award” at the 52nd Trade Day ceremony. Daehan New Pharm is a mid-sized pharmaceutical company specialized in the fields of wellness and chronic disease treatment, focusing on professional pharmaceuticals, veterinary medicines, stem cell technology, and bio-process materials. Through specialization, concentration, and globalization of its core businesses, the company currently generates about 15% of its total performance from overseas markets. Unlike most domestic pharmaceutical companies that mainly export raw materials, Daehan New Pharm has built its presence through exports of finished pharmaceutical products to China, Russia, and Southeast Asia, while also pioneering new markets such as Cuba. By actively targeting emerging economies, the company has expanded its global presence to over 20 countries and nurtured partnerships with more than 60 strategic partners, successfully establishing a worldwide network. This achievement carries great significance as a growth model for mid-sized pharmaceutical firms. Global expansion has not only strengthened Daehan New Pharm’s growth momentum through overseas market development but has also elevated its overall management capabilities. The company’s commitment to global-level quality management, internationally trusted branding, and its success in challenging environments have instilled a strong spirit of challenge and confidence among employees—an invaluable asset beyond the tangible achievement of ten million dollars in exports. This organizational drive has enabled Daehan New Pharm to double its size over the past five years and build sustainable growth capabilities exceeding 20%. The company aims to increase the proportion of overseas business from 15% to over 20% by 2020, advancing beyond export-based globalization toward deeper strategic alliances and direct international expansion. In addition, CEO Bae Gun-Woo was awarded the Minister of Trade, Industry and Energy Commendation in recognition of his leadership and outstanding contribution to expanding finished pharmaceutical exports. Since his appointment in 2008, he has doubled the company’s export volume—from 5.83 million dollars to over 10 million dollars—achieving remarkable export growth and transforming Daehan New Pharm into a globally competitive pharmaceutical exporter.